TY  - BOOK
AU  - Pachipulusu Rajesh
TI  - US FDA regulatory requirements for ANDA submission and review phase assessment
U1  - 615.4 PAC 
PY  - 2019///
KW  - Pharmaceutics - Regulations
N1  - Pramod Kumar T.M
ER  -